Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490260 | ||
| 003 | CHVBK | ||
| 005 | 20210128100504.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0696-0 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0696-0 | ||
| 245 | 0 | 0 | |a Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy |h [Elektronische Daten] |c [Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa] |
| 520 | 3 | |a Abstract : Background: Patients with advanced local-stage, high-grade prostate cancer (Pca) and high pretreatment prostate-specific antigen (PSA) levels have inferior outcomes compared to their counterparts with more favorable clinical characteristics. However, some patients exhibit favorable pathological features or experience long-term PSA-free survival after radical prostatectomy (RP). We retrospectively examined the ability of preoperative characteristics to predict pathological and oncological outcomes in high-risk Pca patients who underwent RP. Methods: We examined data of 1,268 consecutive Pca patients treated with RP alone at 4 hospitals from the Michinoku Urological Cancer Study Group database. Preoperative predictors included age, PSA level, biopsy Gleason score, clinical T stage, and PSA density (PSAD). The outcome measures pathological T stage and PSA-free survival were evaluated by multivariate analysis. Results: We identified 380 high-risk Pca patients, of which 44% patients had extracapsular extension. Logistic regression analysis indicated that PSAD was an independent predictor of adverse pathologic stage. The 5-year PSA-free survival rates were 82.9% for patients with PSAD≤0.468ngmL−1cm−2 and 50.7% for those with PSAD>0.468ngmL−1cm−2 (P<0.0001). Multivariate analyses revealed that PSAD, cT, and the number of preoperative high-risk Pca criteria were independent predictors of PSA-free survival. Conclusions: PSAD may be an independent predictor of advanced pathological features and biochemical recurrence in high-risk Pca patients treated with RP alone. PSAD may be used for further risk stratification of high-risk Pca patients. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Prostate cancer |2 nationallicence | |
| 690 | 7 | |a High-risk |2 nationallicence | |
| 690 | 7 | |a Prostate-specific antigen density |2 nationallicence | |
| 690 | 7 | |a Advanced prostate cancer |2 nationallicence | |
| 690 | 7 | |a Biochemical recurrence-free survival |2 nationallicence | |
| 700 | 1 | |a Koie |D Takuya |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Mitsuzuka |D Koji |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | |
| 700 | 1 | |a Yoneyama |D Takahiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Narita |D Shintaro |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | |
| 700 | 1 | |a Kawamura |D Sadafumi |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | |
| 700 | 1 | |a Kaiho |D Yasuhiro |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | |
| 700 | 1 | |a Tsuchiya |D Norihiko |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | |
| 700 | 1 | |a Tochigi |D Tatsuo |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | |
| 700 | 1 | |a Habuchi |D Tomonori |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | |
| 700 | 1 | |a Arai |D Yoichi |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | |
| 700 | 1 | |a Ohyama |D Chikara |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Yoneyama |D Tohru |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Tobisawa |D Yuki |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 176-181 |x 1341-9625 |q 20:1<176 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0696-0 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0696-0 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Koie |D Takuya |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mitsuzuka |D Koji |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoneyama |D Takahiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Narita |D Shintaro |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kawamura |D Sadafumi |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kaiho |D Yasuhiro |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tsuchiya |D Norihiko |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tochigi |D Tatsuo |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Habuchi |D Tomonori |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Arai |D Yoichi |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ohyama |D Chikara |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoneyama |D Tohru |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tobisawa |D Yuki |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 176-181 |x 1341-9625 |q 20:1<176 |1 2015 |2 20 |o 10147 | ||